Introduction
Immunotherapy utilizing immune checkpoint inhibitors (ICIs) has fundamentally changed the treatment landscape for various solid tumors, significantly improving overall survival (OS). While positive responses to PD-1/PD-L1 blockades have been observed across many malignancies, the efficacy of these therapies in breast cancer (BC) remains comparatively poor. A primary obstacle to improving these outcomes is the incomplete understanding of immune checkpoint expression patterns and their interactions within the breast cancer immune microenvironment. This study aims to map these patterns to identify robust prognostic biomarkers and potential targets for combinational therapy.
Methodology
This research utilized a multi-pronged approach, integrating large-scale bioinformatic analysis with in vitro validation:
- Bioinformatic Screening: The microarray dataset GSE10810 from the Gene Expression Omnibus (GEO) was analyzed to identify differentially expressed genes (DEGs) in breast cancer tissue compared to normal controls. Functional enrichment was performed using Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) via the DAVID database.
- Survival and Correlation Analysis: Data from 657 BC patients in The Cancer Genome Atlas (TCGA) were used to correlate gene expression and mutations with 20-year overall survival (OS). Additionally, expression levels were validated across 1,085 BC patients and 291 healthy controls using the Genotype-Tissue Expression (GTEx) database.
- Experimental Validation: mRNA levels of key checkpoints (PD-L1, STAT1, IDO, IFNγ-R) were measured using Real-time quantitative PCR (RQ-PCR) across a spectrum of cell lines: MCF-10A (non-tumorigenic), MCF-7 (luminal), and MDA-MB-231 (highly aggressive/triple-negative).
Results and Discussion
Pathway Enrichment and Survival Impact
Initial analysis of the GSE10810 dataset identified significant differential gene expression, with functional enrichment pointing toward critical roles in immune response and signaling pathways. Survival analysis revealed that high expression of individual checkpoints—specifically PD-1, PD-L1, STAT1, and CTLA-4—was significantly associated with poor OS. For instance, in the TCGA cohort, patients with high PD-1 expression exhibited a 20-year OS of 0%, compared to 35.09% in the low-expression group ($P=0.002$).
The Power of Co-expression
The study found that the prognostic value of these markers increases when analyzed in combination. Pairwise co-expression of PD-L1 with STAT1, PD-1, or CTLA-4, as well as PD-1 with CTLA-4, was strongly linked to poor clinical outcomes. Notably, the 20-year OS for patients with high co-expression of PD-L1 and STAT1 was 0%, whereas patients with low expression of both markers had an OS of 39.43%.
Subtype and Stage Specificity
Expression patterns varied significantly across clinical stages and molecular subtypes. The highest levels of immune-suppressive markers were found in Basal-like (Triple-Negative) breast cancer, which may explain the aggressive nature of this subtype. Interestingly, the expression of PD-L1 and IDO1 was found to decrease in Stage IV patients compared to earlier stages, suggesting a shift in the immune landscape as the disease progresses to a metastatic state.
In Vitro Validation
RQ-PCR results confirmed the bioinformatic findings. As cell lines progressed from non-tumorigenic to highly aggressive (MCF-10A → MCF-7 → MDA-MB-231), there was a significant increase in the expression of PD-L1 ($P=0.016$) and STAT1 ($P=0.025$). This supports the hypothesis that STAT1 may facilitate anti-tumor immune evasion by upregulating PD-L1.
Conclusion
The findings suggest that the transcriptome-based co-expression of STAT1 and PD-L1 is a potent predictor of poor overall survival in breast cancer patients. While STAT1 is traditionally viewed as a growth inhibitor, its role in upregulating PD-L1 highlights it as a potential target for combinational therapy. Future research should focus on the mechanistic pathways of this interaction and validate these findings at the protein level through immunohistochemistry to facilitate clinical translation.
Summary updated